PAYS · Paysign, Inc.
$14.06
-0.49 (-3.34%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$820.96M
Shares
56.46M
Volume · Oct 28
846.86K
Avg daily vol (3M)
811.57K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.54
Open$14.22
Day$14.10–14.86
52W close$3.18–15.62
Avg vol 30d856K
Short int2.5M · 4.4% float · 2.8d
Short vol60%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 1 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$100.64M
Trailing 12 months
Net income (TTM)
$15.77M
Trailing 12 months
Revenue growth YoY
+48.1%
Year over year
Operating margin
17.0%
Trailing 12 months
P / E (TTM)
55.9
Trailing earnings · reciprocal yield 1.8%
FCF yield
9.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$171.23M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.1%
Year over year · more shares
Price change (1Y)
+148.5%
Trailing year
Short interest
4.4%
Latest settlement · 2.8 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. PaySign reported record Q2 2026 results with revenue up 48.1% to $28.3 million and adjusted EBITDA up 113% to $9.6 million, beating guidance across every line, and raised full-year 2026 revenue guidance to $114–$117 million and adjusted EBITDA to $35–$38 million.
Bullish
- + Q2 revenue grew 48.1% YoY to $28.3 million, beating the high end of guidance.
- + Adjusted EBITDA rose 113% YoY to $9.6 million and margin expanded to 34%, beating guidance.
- + Raised full-year 2026 revenue guidance to $114–$117 million and adjusted EBITDA to $35–$38 million.
- + Patient affordability revenue grew 88.9% YoY to $14.65M with active programs rising to 148 from 97 a year ago.
- + Gross margin expanded 170 bps to 63.3% on operating leverage and a higher pharma mix.
- + Plasma revenue grew 21.4% YoY to $13.04M with average monthly revenue per center up to $7,699, signaling recovery.
Bearish
- − Plasma center count declined by a net 46 centers YoY to 561 due to closures and a customer switching providers.
- − Q2 results included a $990K one-time non-cash benefit from a Gamma acquisition contingent-consideration fair value adjustment that flattered GAAP earnings.
- − Q2 GAAP net income of $6.8M benefited from a low 14.5% effective tax rate tied to stock-price-driven discrete items; Q4 tax rate is expected near 27%.
- − Diluted share count rose to 62.0M from 57.9M YoY, increasing dilution of per-share results.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.5 · elevated
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+77%
above
Price vs 50-day avg
+6%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
+123%
trailing
YTD return
+182%
this year
Relative strength
+118%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
24 of 132 funds reported for Sep 30 · net +69.4K sh shares · +8 new
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Rising
4.44% of float · ▲ +10.5% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
132 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−30%
Y/Y
Gross margin
202%
expanding
EPS growth
+86%
Y/Y
Free cash flow
$51.2M
Valuation
P/E 55.9
rich
Buyback
$5.0M
authorized
Balance sheet
$157.0M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 5, 2026
Full-year revenue
· full-year 2026
Raised
$114M – $117M
May 12, 2026
$106.5M – $110.5M
changed to
Aug 5, 2026
$114M – $117M
prior FY $82.03M
midpoint +40.8% Y/Y
Gross profit margins
· full-year 2026
Raised
62% – 63%
Mar 24, 2026
60% – 62%
changed to
Aug 5, 2026
62% – 63%
Gap net income per diluted share
· full-year 2026
$0.35 – $0.37
prior FY $0.13
midpoint +176.9% Y/Y
Adjusted EBITDA per diluted share
· full-year 2026
Raised
$0.57 – $0.61
Mar 24, 2026
$0.49 – $0.53
changed to
Aug 5, 2026
$0.57 – $0.61
Previous outlook
earlier release
· from the Earnings Call filed May 12, 2026
Still-open targets the latest release did not restate under the same label.
Gross profit margin
· full-year 2026
60% – 62%
Adjusted EBITDA per diluted share
· full-year 2026
$0.49 – $0.53
Prior guidance
period ended
· from the Earnings Call filed Aug 5, 2026
Revenue
· third quarter 2026
$28.5M – $30M
Gross margins
· third quarter 2026
61% – 63%
Guided vs delivered
· last 8 settled
Revenue
Second Quarter 2026
guided $26.2M – $26.7M
$28.25M
Beat +6.8%
Diluted EPS
Second Quarter 2026
guided $0.06 – $0.07
$0.11
Beat +69.2%
Revenue
first quarter of 2026
guided $27M – $27.5M
$28.04M
Beat +2.9%
Fully diluted earnings per share
first quarter of 2026
guided $0.07 – $0.08
$0.09
Beat +20.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+77%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $14 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
24 of 132 funds reported for Sep 30 · net +69.4K sh shares · +8 new
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Rising
4.44% of float · ▲ +10.5% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
132 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $15 · 91%
Range high $16
vs 200-day avg +77%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross Dollar Volume Loaded on Cards | $546M | the three months ended June 30, 2026 filing | — |
| active patient affordability programs | 148 | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $20,201,295 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 35.9% | Six Months Ended June 30, 2026 | — |
| Adjusted operating margin non-GAAP | 22.5% | Six Months Ended June 30, 2026 | — |
| Diluted Adjusted EBITDA per share non-GAAP | $0.16 | Q2 2026 | — |
| EBITDA non-GAAP | $18,655,036 | Six Months Ended June 30, 2026 | — |
| EBITDA margin non-GAAP | 33.1% | Six Months Ended June 30, 2026 | — |
| gross dollar load volume growth | 24.3% | Q2 2026 | — |
| gross spend volume growth | 24.2% | Q2 2026 | — |
| net plasma center count | 561 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Software - Infrastructure — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PAYS
this stock
Paysign, Inc.
|
$820.96M | +182.3% | -30.4% | 55.9 | 4.4% |
|
MSFT
Microsoft Corp
|
$3.95T | +9.9% | +6.9% | 29.6 | 0.9% |
|
PLTR
Palantir Technologies Inc.
|
$477.56B | +11.8% | +56.2% | 169.9 | 2.3% |
|
ORCL
Oracle Corp
|
$394.69B | -33.0% | +17.3% | 20.5 | 1.6% |
|
PANW
Palo Alto Networks Inc
|
$328.59B | +118.1% | +29.0% | — | 2.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PAYS | -4.4% | +13.2% | +122.7% | +7.9% | +182.3% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -4.5% | +12.4% | +117.8% | +6.9% | +169.5% |
Capital returns
Buyback program
· as of Mar 31, 2016
Authorized
$5.00M
Spent (derived)
—
Remaining
shares 258,000
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1496443
CUSIP
70451A104
13F (30d)
23 filings
23 filers
Visit website
Investor relations